PBAC's latest decision on Paclitaxel, nanoparticle albumin-bound: Recommended with restriction (2019). Considered for A 250 mg strength of nanoparticle albumin-bound paclitaxel for Stage IV (metastatic) adenocarcinoma of the pancreas in combination with gemcitabine, metastatic breast cancer, and HER2 positive breast cancer.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2008
Submissions
2
2008 → 2019
Eligible population
Patients with Stage IV (metastatic) adenocarcinoma of the pancreas, metastatic breast cancer, or HER2 positive breast cancer, with ECOG performance status score of 2 or less, with no prior PBS-subsidised therapy.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
Other
Economic model
Not modelled
ICER note
Minor submission with no economic analysis presented. However, the PBAC recalled that at its March 2014 meeting, the base case ICER for the 100 mg vial was $45,000 to $75,000/LYS.
ICER (historical)
$45k/QALY–$75k/QALY in an earlier submission (2008) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Dec 2008: Recommended with restriction · Authority Required — ICER $75k/QALY
Mar 2019: Recommended with restriction · Authority Required